GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (ASX:PAR) » Definitions » Long-Term Debt

Paradigm Biopharmaceuticals (ASX:PAR) Long-Term Debt : A$0.18 Mil (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Paradigm Biopharmaceuticals Long-Term Debt?

Paradigm Biopharmaceuticals's Long-Term Debt for the quarter that ended in Dec. 2023 was A$0.18 Mil.

Paradigm Biopharmaceuticals's quarterly Long-Term Debt declined from Dec. 2022 (A$0.29 Mil) to Jun. 2023 (A$0.00 Mil) but then increased from Jun. 2023 (A$0.00 Mil) to Dec. 2023 (A$0.18 Mil).

Paradigm Biopharmaceuticals Long-Term Debt Historical Data

The historical data trend for Paradigm Biopharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paradigm Biopharmaceuticals Long-Term Debt Chart

Paradigm Biopharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only - - - - -

Paradigm Biopharmaceuticals Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.29 - 0.18 -

Paradigm Biopharmaceuticals  (ASX:PAR) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Paradigm Biopharmaceuticals Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Paradigm Biopharmaceuticals's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Paradigm Biopharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (ASX:PAR) » Definitions » Long-Term Debt
Comparable Companies
ASX:BOT ASX:RAC ASX:OPT ASX:PYC ASX:PIQ ASX:RCE ASX:BIT ASX:CU6 ASX:ALA ASX:DXB OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
PBIGF:USA
Address
500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Website
https://www.paradigmbiopharma.com
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulphate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.